HIK.L - Hikma Pharmaceuticals PLC

LSE - LSE Delayed price. Currency in GBp
1,437.10
+61.10 (+4.44%)
As of 11:59AM BST. Market open.
Stock chart is not supported by your current browser
Previous close1,376.00
Open1,391.50
Bid1,433.50 x 16300
Ask1,436.00 x 34600
Day's range1,384.80 - 1,440.50
52-week range814.20 - 1,618.25
Volume157,483
Avg. volume608,253
Market cap3.469B
Beta0.85
PE ratio (TTM)N/A
EPS (TTM)-351.30
Earnings date15 Aug 2018
Forward dividend & yield0.34 (2.41%)
Ex-dividend date2018-04-05
1y target est15.92
  • 2 super growth stock I’d buy with £5,000 today
    Fool.co.uk3 days ago

    2 super growth stock I’d buy with £5,000 today

    Just £5,000 could help you make a fortune with these super growth stocks.

  • Reuterslast month

    Hikma reaffirms full-year revenue forecast, cites better generics business

    The drugmaker, which was forced to cut revenue guidance for its generics business three times in 2017, said it continued to expect revenue from the business to be between $550 million (407 million pounds) and $600 million in 2018. Sigurdur Olafsson, former generics chief at drug giant Teva Pharmaceuticals (TEVA.TA), was named Hikma's chief executive officer in February. The company suffered a setback in March for its generic version of GlaxoSmithKline's (GSK.L) blockbuster lung drug Advair, after the U.S. Food and Drug Administration asked Hikma to conduct a further clinical study evaluating the drug, dashing hopes to get it to the market this year.

  • Reuters - UK Focuslast month

    Hikma reaffirms full-year revenue forecast, cites better generics business

    Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) on Friday reaffirmed its revenue guidance for the full year, noting its generics business was performing better due to a favourable product mix, despite continued pricing pressure in the United (Shenzhen: 000925.SZ - news) States. The drugmaker, which was forced to cut revenue guidance for its generics business three times in 2017, said it continued to expect revenue from the business to be between $550 million and $600 million in 2018. Sigurdur Olafsson, former generics chief at drug giant Teva Pharmaceuticals, was named Hikma's chief executive officer in February.

  • Reuters - UK Focus3 months ago

    BUZZ-Hikma: brokers raise ratings, PTs

    ** Jefferies raises recommendation on drugmaker to "hold" from "underperform" ** Despite challenging industry fundamentals persisting into 2018, guidance gives a floor to expectations, ...

  • Reuters3 months ago

    Drugmaker Hikma's FY profit, revenue meet expectations; shares rise

    The company has struggled due to persistent price pressures in the U.S. market and was forced to cut revenue guidance for its generics business thrice in 2017. Hikma's problems were further compounded by a delay in the launch of its generic version of GlaxoSmithKline's (GSK.L) blockbuster lung drug Advair. The U.S. Food and Drug Administration on Monday asked Hikma to conduct a further clinical study evaluating the drug.

  • Reuters - UK Focus3 months ago

    Drugmaker Hikma sees more layoffs in generics business

    Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) is expected to cut more jobs in its generics business to save costs, the Jordan-based drugmaker said on Wednesday, after reporting full-year profit and revenue largely in line with expectations. Hikma, which was forced to cut revenue guidance for its generics business three times in 2017 due to pricing pressures in the United States, has cut 200 jobs since it bought the business from Boehringer Ingelheim in 2016, CFO Khalid Nabilsi said in a call to Reuters. Nabilsi added that another 200 jobs would go as a result of the consolidation of its generics' manufacturing facilities and U.S. distribution centres.

  • Reuters - UK Focus3 months ago

    FTSE 100 lags Europe on miners and energy, Just Eat goes cold

    Early gains for the FTSE 100 quickly dissipated and it was up just 0.1 percent by 0942 GMT, missing out on a rally lifting European stocks, with Germany's DAX up 0.7 percent. Falls in miners and oil majors had the biggest influence as the price of metals and crude fell.

  • Reuters - UK Focus3 months ago

    BUZZ-Hikma, Vectura: Shares down, generic Advair delayed again

    ** Shares of Hikma Pharmaceutical fall 6 pct at open, now down 2 pct, with Vectura down 5.3 pct ** Hikma fails to find quick resolution in dispute with U.S. FDA over plans to launch a generic copy of GlaxoSmithKline's ...

  • Reuters3 months ago

    GSK wins new reprieve as Hikma's generic Advair delayed again

    The Jordan-based firm said on Monday it expected to submit a response to the U.S. Food and Drug Administration (FDA) with new clinical data in 2019. Hikma's partner on the project, Vectura (VEC.L), said this meant a potential approval and launch of the generic inhaled medication could come in 2020 if all goes well. Shares in Hikma fell 1 percent in early trade, while Vectura lost 5 percent.

  • Reuters - UK Focus3 months ago

    GSK wins new reprieve as Hikma's generic Advair delayed again

    GlaxoSmithKline (Other OTC: GLAXF - news) has won a further reprieve for its blockbuster Advair lung drug after U.S. regulators insisted Hikma Pharmaceuticals (Frankfurt: A0HG69 - news) conduct a further clinical study evaluating its generic version of the drug. The Jordan-based firm said on Monday it expected to submit a response to the U.S. Food and Drug Administration (FDA) with new clinical data in 2019. Hikma's partner on the project, Vectura, said this meant a potential approval and launch of the generic inhaled medication could come in 2020 if all goes well.

  • Reuters - UK Focus4 months ago

    Disappointing HSBC update, weak miners keep FTSE flat

    The FTSE index ended the session flat at 7,246.77 points, lagging a broadly positive European market, while Britain's mid-cap index added 0.8 percent, helped by news of a possible bid for software firm Fidessa. HSBC fell 3 percent after Europe's biggest lender by market value reported a jump in annual pre-tax profit that missed expectations and unveiled a plan to raise up to $7 billion over the next four months to bolster its capital base.

  • Reuters4 months ago

    Drugmaker Hikma names former Teva executive Olafsson as CEO; shares up

    Hikma said its current chairman and CEO, Said Darwazah, would become executive chairman. Shares of Hikma rose as much as 5 percent in early trading on the London Stock Exchange. Olafsson's appointment comes at a time when Hikma is facing higher price erosion levels than the rest of the industry that prompted it to lower the revenue guidance for its generics business twice last year.

  • Reuters4 months ago

    Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed

    GlaxoSmithKline has won another reprieve for its blockbuster Advair lung drug after U.S. regulators delayed approval of a generic copy from Novartis's Sandoz division. The Swiss drugmaker said in an emailed statement on Thursday it had received a so-called complete response letter from the U.S. Food and Drug Administration (FDA) and a generic Advair launch this year was now "highly unlikely".

  • Reuters - UK Focus4 months ago

    Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed

    GlaxoSmithKline (Other OTC: GLAXF - news) has won another reprieve for its blockbuster Advair lung drug after U.S. regulators delayed approval of a generic copy from Novartis's Sandoz division. The Swiss drugmaker said in an emailed statement on Thursday it had received a so-called complete response letter from the U.S. Food and Drug Administration (FDA) and a generic Advair launch this year was now "highly unlikely".

  • Reuters5 months ago

    Drugmaker Dermapharm gears up for likely first German IPO of 2018

    German drugmaker Dermapharm is preparing for an initial public offering (IPO), probably stealing a march on much larger Siemens' (SIEGn.DE) healthcare unit Healthineers as the first stock market flotation in Germany this year. Dermapharm, which makes generic drugs, cosmetics, dietary products and medical devices, said on Monday it aimed to raise about 100 million euros ($122 million) in fresh capital to fund growth during an IPO in the first half of 2018. The family owners will also sell shares, and after the IPO 25 percent of the company will be in the hands of public investors, Dermapharm said.

  • Reuters - UK Focus5 months ago

    Drugmaker Dermapharm gears up for likely first German IPO of 2018

    German drugmaker Dermapharm is preparing for an initial public offering (IPO), probably stealing a march on much larger Siemens (BSE: SIEMENS.BO - news) ' healthcare unit Healthineers as the first stock market flotation in Germany this year. Dermapharm, which makes generic drugs, cosmetics, dietary products and medical devices, said on Monday it aimed to raise about 100 million euros ($122 million) in fresh capital to fund growth during an IPO in the first half of 2018. The family owners will also sell shares, and after the IPO 25 percent of the company will be in the hands of public investors, Dermapharm said.

  • Reuters - UK Focus6 months ago

    Hikma wins right to market Roche drug copy in Middle East and North Africa

    Dec (Shanghai: 600875.SS - news) 19 (Reuters) - Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) has won exclusive rights to distribute and market its third biosimilar drug - a copy of Roche's blood cancer treatment Rituxanin - in the Middle East and North African markets, it said on Tuesday. The Jordan-based drugmaker agreed on the licensing deal with Celltrion to market the South Korea-based biopharmaceutical firm's Truxima, a copy of Roche's blockbuster blood cancer medicine, also known as MabThera. Truxima, the first biosimilar cancer drug to hit the European market in February, is used to treat patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis and and microscopic polyangiitis.

  • Reuters7 months ago

    Takeaway app Delivery Hero joins European index in tech-heavy rejig

    German takeaway app Delivery Hero, which listed five months ago, will join the STOXX 600 benchmark index in December as rapidly rising tech stocks dominate its quarterly reshuffle. Delivery Hero's stock is up by around 40 percent from its IPO price, raising its market capitalisation to 6.7 billion euros ($7.9 billion). Along with companies such as Just Eat, which is expected to be promoted to Britain's FTSE 100 index later on Wednesday, Delivery Hero's addition reflects consumer demand for cheap, efficient, on-demand services to order food.

  • Reuters - UK Focus7 months ago

    European shares suffer worst day since June as earnings underwhelm

    MILAN/LONDON, Nov 9 (Reuters) - European shares fell on Thursday as a series of underwhelming earning updates, including from industrial giant Siemens, prompted investors to take profits out of a market still trading near two-year highs. The pan-European STOXX 600 benchmark index fell 1.1 percent, suffering its biggest daily loss since end-June, while Germany's DAX fell 1.5 percent. The STOXX 600 is up 7.9 percent so far this year following a rally that has been fuelled by a combination of strong economic data, solid earnings and easing political fears.

  • Reuters - UK Focus7 months ago

    Britain's FTSE under pressure as Burberry revamps its strategy

    A drop in luxury group Burberry weighed on the UK's top share index on Thursday, which was stuck below a five-month high as results were the main focus. Britain's blue-chip FTSE 100 index was flat in percentage ...

  • Reuters7 months ago

    Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

    The dispute between the Jordan-based firm, its partner Vectura (VEC.L) and the U.S FDA delays any eventual approval of the generic version of the drug. Shares of Hikma were down 5.5 percent at market open, while Vectura shares were down about 10 percent.

  • Reuters - UK Focus7 months ago

    Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

    Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline (Other OTC: GLAXF - news) 's popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time. The dispute between the Jordan-based firm, its partner Vectura and the U.S FDA delays any eventual approval of the generic version of the drug. Shares (Berlin: DI6.BE - news) of Hikma were down 5.5 percent at market open, while Vectura shares were down about 10 percent.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes